Research Article

DPYD, TYMS, TYMP, TK1, and TK2 Genetic Expressions as Response Markers in Locally Advanced Rectal Cancer Patients Treated with Fluoropyrimidine-Based Chemoradiotherapy

Table 3

Correlations between clinicopathological features and response status in 60 locally advanced rectal cancer patients.

CharacteristicsTotal casesNonresponseResponse value
(%) (%) (%)

Gender
 Female26 (43.3%)7 (33.3%)19 (48.7%)0.251
 Male34 (56.7%)14 (66.7%)20 (51.3%)
Age (years)
 <6022 (36.7%)8 (38.1%)14 (35.9%)0.886
 ≥6038 (63.3%)13 (61.9%)25 (64.1%)
Tumor size
 <5 cm46 (76.7%)14 (66.7%)32 (82.1%)0.179
 ≥5 cm14 (23.3%)7 (33.3%)7 (17.9%)
Stage (UICC)a
 II12 (20.0%)5 (23.8%)7 (17.9%)0.737
 III48 (80.0%)16 (76.2%)32 (82.1%)
Clinical T-stage
 T354 (90.0%)19 (90.5%)35 (89.7%)1.000
 T46 (10.0%)2 (9.5%)4 (10.3%)
Clinical N-stage
 N012 (20.0%)5 (23.8%)7 (17.9%)0.846
 N123 (38.3%)8 (38.1%)15 (38.5%)
 N225 (41.7%)8 (38.1%)17 (43.6%)
Chemotherapy
 Capecitabine36 (60.0%)10 (47.6%)26 (66.7%)0.151
 5-FU24 (40.0%)11 (52.4%)13 (33.3%)
Time intervals of CCRT to operation
 <6 weeks20 (33.3%)8 (38.1%)12 (30.8%)0.566
 ( weeks)
 ≥6 weeks40 (66.7%)13 (61.9%)27 (69.2%)
 ( weeks)
Differentiationb
 WD2 (3.3%)0 (0.0%)2 (5.1%)0.653
 MD47 (78.3%)17 (81.0%)30 (76.9%)
 PD4 (6.7%)2 (9.5%)2 (5.1%)
 Unclassified7 (11.7%)2 (9.5%)5 (12.8%)
Distance to anus
 <5 cm38 (63.3%)11 (52.4%)27 (69.2%)0.196
 ≥ 5 cm22 (36.7%)10 (47.6%)12 (30.8%)
Vascular invasion
Yes52 (86.7%)18 (85.7%)34 (87.2%)1.000
No8 (13.3%)3 (14.3%)5 (12.8%)
Perineural invasion
 Yes40 (66.7%)10 (47.6%)30 (76.9%)0.022
 No20 (33.3%)11 (52.4%)9 (23.1%)
Pre-CCRT CEA
 >2.5 ng/mL44 (73.3%)15 (71.4%)29 (74.4%)0.807
 ≤2.5 ng/ml16 (26.7%)6 (28.6%)10 (25.6%)
Pre-CCRT CEAc
 >5 ng/mL27 (45.0%)10 (47.6%)17 (43.6%)0.765
 ≤5 ng/mL33 (55.0%)11 (52.4%)22 (56.4%)
Chipd result
 Negative21 (35.0%)17 (81%)4 (10.3%)<0.001
 Positive39 (65.0%)4 (19%)35 (89.7%)

UICC: The American Joint Commission on Cancer/International Union Against Cancer (AJCC/UICC, 2002).
bWD: well differentiated, MD: moderately differentiated, PD: poorly differentiated.
cCEA: carcinoembryonic antigen.
dChip: panel of multiple genetic biomarkers.